Miraculins Announces the Appointment of Chris Carmichael as Chief Financial Officer
January 18, 2016 (Source) — Miraculins Inc. (TSXV: MOM) (the “Company”), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs announces that effective today, Mr. Christopher Carmichael, CPA, CGA, has been appointed Chief Financial Officer (CFO) of the Company. Mr. Carmichael replaces Mr. James Kinley, who has served as CFO since December 23, 2011 under a management services agreement between the Company and Genesys Venture Inc., which recently expired. The appointment of Mr. Carmichael is subject to regulatory approval.
Mr. Carmichael is the President of CRIS Inc., a firm that provides financial reporting, corporate secretarial, and CFO services to TSX, TSXV and CSE companies. Mr. Carmichael is currently the CEO of Bradstone Capital Corp., a merchant banking organization, and the CFO and Director of Connected in Motion, a Canadian charitable organization for adults living with Type 1 Diabetes. From 2003 to 2009, Mr. Carmichael was CFO of Fountain Asset Corp. (formerly GC-Global Capital Corp.), a TSXV listed merchant banking organization. “Given my association with the Canadian diabetes community, I look forward to working with Miraculins and advising on the company’s go-forward strategy related to its pre-diabetes and Type 2 diabetes non-invasive screening technology,” said Carmichael.
Get our daily investorintel update
“The board recognizes and appreciates James Kinley’s contributions and dedication in his role as CFO over the past four years and we wish him well in the future,” said Harry Bloomfield, Chairman of the Miraculins board.
Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. The Company’s Scout DS(R) device has been regulatory cleared in certain markets both as a clinical tool to assist in the identification of both prediabetes and type 2 diabetes, and is the first non-invasive testing system designed to provide a highly sensitive and convenient method for measuring prediabetes/type 2 diabetes related biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress. Unlike current testing methods, a Scout DS(R) test requires no blood draw, no fasting, and no waiting for a lab result. The product has been used and validated in thousands of patients around the world. For more information visit www.miraculins.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Scout(R) is a registered trademark of Miraculins Inc. All Rights Reserved. 2016.
InvestorIntel is a trusted source of reliable information at the forefront of emerging markets that brings investment opportunities to discerning investors.